UnknownNot Applicable

Evaluation of Blood Platelet Indices,Platelet Aggregation in the Activity of IBD Patients on Biological Treatment

120 participantsStarted 2022-06-05

Plain-language summary

ulcerative colitis and Crohn's disease, the two major forms of inflammatory bowel disease, are chronic, idiopathic, relapsing inflammatory conditions of the gastrointestinal tract. The mechanism is multifactorial and may result from the combined interaction of environmental, genetic, epithelial barrier defects, dysregulated immune responses, and microbial factors

Who can participate

Age range21 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. All patients diagnosed with inflammatory bowel disease ulcerative colitis or crohn's disease
✓. All IBD patients received biological treatment
✓. All IBD patients controlled with conventional treatment

Exclusion criteria

✕. IBS patients
✕. IBD Patients with: a) another autoimmune disease like ITP and SLE B) Bleeding tendency as hemophilia or thrombophilia C) Previous thrombotic events or on anticoagulants or antiplatelet drugs D) With another comorbidity as liver cell failure, respiratory failure, renal failure and cardiac failure

What they're measuring

detect of disease activity of IBD patients received biological treatment in the start and in 14 weeks after treatment compared to whose controlled by platelet indices and platelet lymphocytic ratio.

Timeframe: about 14 weeks after start of treatment of inflixmab

Trial details

NCT IDNCT05406934

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-06-05

View on ClinicalTrials.gov More Bowel Disease trials